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A B S T R A C T
Background: More men are living following a prostate cancer (PCa) diagnosis. They may need support to
maximize the quality of their survival. Physical and psychological impacts of PCa are widely documented. Less is
known about social impacts. We aimed to identify key factors associated with social distress following PCa.
Methods: The Life After Prostate Cancer Diagnosis study is a UK national cross-sectional survey of men 18–42
months post diagnosis of PCa. Men (n=58 930) were invited to participate by their diagnosing cancer centre
including 82% of English NHS Trusts (n= 111) and 100% of all Health Boards in Northern Ireland (n=5),
Scotland (n=14) and Wales (n= 6). Social distress was measured using the Social Difficulties Inventory (SDI-
21), 16 item Social Distress scale with men assigned to ‘socially distressed’/‘not socially distressed’ groups,
according to published guidelines. Clinical and sociodemographic variables were collected from self-report and
cancer registries.
Results: Response rate 60.8% (n= 35 823) of whom 97% (n=29 351) completed the Social Distress scale
(mean age= 71.2; SD=7.88). The proportion of ‘socially distressed’ men was 9.4%. Multivariable logistic
regression analysis revealed unemployment versus employment (odds ratio (OR): 11.58 [95% CI 9.16–14.63])
and ≥3 co-morbidities versus none (OR: 5.37 [95% CI 4.61–6.27]) as key associations. Others were Androgen
Deprivation Therapy, External Beam Radiotherapy in combination with another treatment, age, prior mental
health problems and living in a socio-economically deprived area.
Conclusion: Most men following PCa are socially resilient. A simple checklist could help clinicians identify men
at risk of social distress.
1. Introduction
Prostate cancer (PCa) is the second most common cancer in men in
the developed world. Over recent decades PCa incidence and pre-
valence has increased considerably across Europe and in the United
States (US) following introduction of prostate-specific antigen (PSA)
testing [1]. The physical symptoms and late effects of the disease and
treatments are widely documented, particularly concerning sexual,
urinary and bowel function [2,3]. Depression and anxiety are re-
cognised psychological issues [4]. Less is known about the social impact
of PCa diagnosis and treatment on everyday life, at home, at work,
financially and recreationally [5]. As cancer patients surviving longer,
they must be supported to maximise their rehabilitation [6].
In the United Kingdom (UK), large scale Patient Reported Outcome
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Measure (PROM) surveys linked with clinical data have been re-
commended to examine the scale of psychosocial issues faced by cancer
survivors and to inform delivery of clinical care, service planning and
policy decision making [7,8]. An English national survey of colorectal
cancer survivors allowed for complex predictive analyses of social
distress using the Social Difficulties Inventory, (SDI-21) [9,10], a
questionnaire designed to measure everyday social impacts following
cancer diagnosis [11]. Major associations with social distress were
multi-morbidity, unemployment, advanced disease, younger age and
living in more deprived areas. Pilot surveys have included social dis-
tress assessment but the numbers surveyed precluded detailed multi-
variable analyses [12]. The National Health Service (NHS) England
pilot of 866 men with PCa, one to five years post diagnosis, demon-
strated a trend for men with PCa to be less socially distressed than
patients from other tumour groups [12].
Ideally, screening programs integrated into routine care might
identify men who would benefit from psychosocial support or re-
habilitation. The UK National Cancer Survivorship Initiative promoted
including social assessment as part of comprehensive programmes of
supportive care [8]. In the United States, a taskforce examined evidence
and made recommendations regarding cancer rehabilitation to meet the
needs of cancer survivors [13]. One barrier identified to integrating
rehabilitation into oncology care was a lack of PROMs for assessment
within the social domain (e.g. communication, employment, commu-
nity and social participation). In Canada, the Distress Assessment and
Response Tool (DART) program has overcome many challenges faced in
routine distress screening, including choice of assessment tools [14].
DART includes the SDI-21 which covers the social domain issues out-
lined above, and has demonstrated usefulness by being a key indicator
of suicidal ideation and intention [15]. However, many cancer care
services may be unable to introduce routine psychosocial and re-
habilitation screening due to practical and financial challenges. Iden-
tifying ‘at risk’ patients using known factors associated with social
distress may be a more realistic option for many clinicians. As PCa is
one of the most common cancers with which men may live for many
years following diagnosis, early identification of men who may benefit
from support and rehabilitation must become a key component of
follow-up care.
The Life After Prostate Cancer Diagnosis (LAPCD) study is a large
UK-wide evaluation of quality of life (QoL) in men diagnosed with PCa
[16]. The aim of this sub-study is to utilise LAPCD data to identify key
factors associated with social distress in men with PCa, thus informing
clinical practice and enabling prompt recognition of the most vulner-
able men likely requiring support to optimise their quality of survival.
2. Material and methods
2.1. Study design
The LAPCD study design has been detailed previously [16]. In brief,
men with PCa between 18 and 42 months post diagnosis identified
through national cancer registration systems in England, Wales and NI,
and through hospital activity data in Scotland, were eligible to parti-
cipate. They were invited to participate by their diagnosing cancer
centre. Two reminders were sent to non-responders. The survey was run
between October 2015 and November 2016. Ethical approval was
provided by: Newcastle & North Tyneside 1 Research Ethics Committee
(15/NE/0036), Confidentiality Advisory Group (15/CAG/0110), NHS
Scotland Public Benefit and Privacy Panel (0516-0364), and NHS R&D
approval from Wales, Scotland and Northern Ireland. Informed consent
was accepted as given on return of a completed survey.
2.2. Main outcome and measures
The survey comprised validated PROMs covering generic and PCa
specific domains alongside psychological and social outcomes.
Participants were asked to provide information about their cancer di-
agnosis and treatment in addition to a number of sociodemographic
questions. For full survey content see supplementary file 01.
2.2.1. The Social Difficulties Inventory (SDI-21)
The main outcome of social distress was measured using the SDI-21,
developed specifically for cancer patient assessment [11]. The SDI-21
has been positively reviewed [17] and used in a number of previous
national surveys [10,12]. The 21 items have four response options (0 –
no difficulty through to 3 – very much difficulty). Sixteen items form a
scale named Social Distress (SD-16) with a range of scores of 0–44 with
a cut-point indicating “meaningful Social Distress of ≥10 (derived
following social worker assessment) [18].” Men were categorised into
one of two groups (socially distressed/not socially distressed) based on
this cut-point. Within the SD-16 there are three subscales: Everyday
Living (6 items), Money Matters (5 items) and Self and Others (5 items)
[19]. There are five single items, of which two were included in the
LAPCD survey (Plans to have a family and Holidays). Three single items
(Sexual matters, Where you live, Other) were omitted with permission
of the originators (PW, PS) to avoid item duplication within other in-
cluded scales and to reduce participant burden. The items are num-
bered 31–48 in supplementary file 01.
2.2.2. Clinical and sociodemographic variables
Cancer stage grouping (I–IV) at time of diagnosis was provided from
national population-based cancer registries. A measure of area-based
socio-economic deprivation was derived from postcodes of residence
using Index of Multiple Deprivation (IMD) [20–23]. Participant self-
reported Long Term Conditions (LTCs) from a list of 14 (e.g. diabetes,
heart disease) (supplementary file 01, question 84) were counted and
categorised as 0 1, 2,or ≥3 comorbidities, height and weight (to gen-
erate Body Mass Index (BMI)), ethnicity, marital status, employment
status, sexuality, carer status and whether or not in the past they had
consulted a health-care professional for problems with emotions or
nerves or use of alcohol or drugs (referred to from here on as mental
health-related problems). Age at the time of the survey was self-re-
ported, and where missing supplemented by cancer registration re-
cords. Four age groups were generated (years:< 60, 60–69, 70–79,
80+). PCa treatments (e.g. surgery, radiotherapy, androgen depriva-
tion therapy (ADT), systemic (chemotherapy/Abiraterone/En-
zalutamide) and monitoring (active surveillance (AS), watchful
waiting)) were participant self-reported. Based on these self-reports,
several groups of men were excluded from the analyses where their
responses indicated they were unsure about the specific treatment type
(s) received (supplementary file-02).
2.3. Statistical analyses
Analyses were performed using Stata version 15.0 (StataCorp, TX,
USA). Missing SDI-21 data were imputed with the mean responses
within each SDI-21 subscale if ≥50% of items on the subscales were
complete.
Descriptive statistics were used to compare the characteristics of
responders and non-responders to the SDI-16, SD-16 subscales and the
two single items. Chi-square analyses compared categorical variables.
Univariable analyses assessed associations between the socio-
demographic and treatment variables described above and social dis-
tress. Multivariable logistic regression analyses were performed to as-
sess associations with the independent sociodemographic and treatment
variables and distress according to SD-16 (binary outcome<10 vs.
≥10) and each of the subscales (cut-points for each derived from earlier
work: Everyday Living ≥5, Money Matters ≥2, Self and Others ≥3)
[10].
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3. Results
3.1. Response rates
All health boards in Scotland, Wales, NI and 111/136 NHS Trusts in
England participated (supplementary file-03) resulting in inclusion of
58,930 men, which is approximately 82% of all men diagnosed in the
UK with PCa during the study period. The response rate was 60.8%
(35,823/58,930). After excluding the men who did not report or were
unsure about their received treatments, (n= 5709; 15.9%), 30,114
survey responses were available for analysis. Of those, 97%
(n=29,351) contained the full SD-16 and completion rates for single
items were: plans to have a family (87.8%); plans to travel or take a
holiday (97.7%). Of the men not providing treatment information,
14.3% (n=772) were above the SD-16 cut-point indicating significant
social distress (supplementary file-02).
3.2. Characteristics of SD-16 respondents
SD-16 respondent’ characteristics are presented in Table 1. The
mean age of the men was 71.2 years (SD=7.88) with most ≥60 years
old (92.6%) and white (94.4%). The proportion of men under 60 years
old who were unemployed was 10.6% compared with the older men
(1.3%). Those living in affluent areas were over-represented compared
with non-responders. Non-responders to the SD-16 were more likely to
be non-white (p < .001) and living in areas of greater deprivation
(p < .001). The percentage of missing data was less than 3% for par-
ticipant characteristics, barring BMI (calculated from participant self-
reported weight and height) at 7.2% and for stage of PCa at the time of
diagnosis (from cancer registration records; 13.8%).
3.3. SD-16
The median SD-16 score was 1, range 0–44 and Interquartile range
(IQR) 0–4. Just under 10% of men (2766/29,351) indicated social
distress (SD-16 score ≥10). The proportion of men indicating social
distress and univariable associations are shown in Table 2. Table 3
presents results of the multivariable logistic regression. Being un-
employed at the time of survey was most strongly associated with social
distress, followed by having ≥3 comorbid LTCs. Other clear associa-
tions with social distress included External Beam Radiotherapy (EBRT)
in addition to another treatment, ADT, being under 60 years old, having
ever consulted a healthcare professional for mental health-related
problems and living in areas of greater socio-economic deprivation. To
a lesser extent, separated/divorced, having stage IV disease, having
caring responsibilities, and a BMI > 30 were also associated with so-
cial distress.
3.4. SD-16 subscales
Multivariable logistic regression indicated unemployment was most
strongly associated with distress on all three subscales (Table 4).
Having ≥3 comorbid LTCs was related to significant distress across all
subscales but especially Everyday Living. Type of treatment impacted
on all subscales, with systemic therapy and ADT alone having a greater
influence on Everyday Living and Self and Others than Money Matters.
Other factors independently associated with distress on all three sub-
scales included having seen a healthcare professional for mental health-
related problems, living in an area of greater socio-economic depriva-
tion, having caring responsibilities, being diagnosed with stage IV PCa
and having a BMI > 30. Older age (80+) was a significant risk factor
for distress on the Everyday Living subscale but had a protective effect
on the other two subscales. Being of non-white ethnicity was associated
with distress on the Money Matters subscale only. See Table 4 for full
results.
3.5. Single items
The percentages of men reporting ‘quite a bit of difficulty’ or ‘very
much difficulty’ were 4.2% for “Plans to have a family” and 12.3% for
“Holidays”.
4. Discussion
This is the largest study we know of to date, examining the social
impact of PCa on those living with and beyond the disease.
Reassuringly, and of importance, is the finding that most men were
socially resilient following a diagnosis of PCa. The key associations with
social distress were non-cancer related, such as unemployment and
Table 1
Characteristics of the men who completed the SD-16.
Variables UK-wide men with prostate
cancer (N=29,351)
Characteristics N (%) Missing
Age < 60 years 2,163 7.4 2
60–69 years 10,191 34.7
70–79 years 12,644 43.1
80+ years 4,351 14.8
Deprivation (Quintile of
socio-economic
deprivation)
Most affluent 1 7,960 27.8 668
2 7,788 27.1
3 6,021 21
4 4,192 14.6
Least affluent 5 2,722 9.5
Ethnicity White 27,813 97.3 752
Non-White 786 2.7
Long term conditions 0 8,577 29.2 0
1 10,353 35.3
2 5,798 19.8
3+ 4,623 15.8
Consulted for mental
health related
problem
Yes 4,932 17.2 682
No 23,737 82.8
Caring responsibilities Yes 6,846 24.2 1025
No 21,480 75.8
Legal marital status Married/Civil
Partner
23,411 80.5 264
Separated/
Divorced
2,109 7.3
Widowed 2,126 7.3
Single 1,058 3.6
Other 383 1.3
Employment status Employed 5,974 20.9 784
Unemployed 582 2
Retired 21,804 76.3
Other 207 0.7
Body Mass Index (Kg/m2) < 25 8,409 30.9 2096
25–30 13,126 48.2
> 30 5,720 21
Prostate cancer stage at
diagnosis
I/II 16,338 64.6 4061
III 5,801 22.9
IV 3,151 12.5
Treatment Active
surveillance
2,869 9.8 0
Surgery alone 6,919 23.6
EBRT alone 2,442 8.3
Brachytherapy
alone
1,190 4.1
ADT alone 2,990 10.2
Watchful waiting 2,211 7.5
EBRT & ADT 7,337 25
Surgery & EBRT/
ADT
2,279 7.8
ADT & systemic 609 2.1
EBRT & systemic 505 1.7
Key: SD-16: Social Distress scale. EBRT: External beam radiotherapy. ADT:
Androgen deprivation therapy. Systemic (chemotherapy/Abiraterone/
Enzalutamide). Long term conditions reported were counted from a list of 14
and categorised into one of the four groups (0, 1, 2, ≥3).
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multi-morbidity.
As found in the colorectal cancer English national survey, being in
either the youngest (< 60 years) or oldest (≥80 years) age groups was
associated with higher levels of distress [10]. This may well be a re-
flection of ‘life stage’, with younger men more likely to have financial
commitments (e.g. paying a mortgage, needing to provide an income)
and having responsibilities for children [24]. In this study, younger
men recorded higher levels of distress in the Money Matters subscale.
They were also much more likely to report being unemployed than men
over 60 years. Many of the younger men had changed employment
status since diagnosis [25]. Unemployed men had almost twelve times
higher odds of experiencing social distress than their employed or
retired counterparts. The median age of men in Europe and in the
United States of America (USA) at the time of their PCa diagnosis is
decreasing [1]. This means more men of employment age will receive a
PCa diagnosis than previously. This expanding group of younger men,
and the smaller number of unemployed older men may benefit from
information, signposting and advice regarding employment and fi-
nancial matters from key trained staff [26]. This would need careful
introduction, as research suggests men may be resistant to intervention
for fear of losing control or due to striving for ‘normality’ [27]. For
Table 2
Proportion of respondents who scored ≥10 on SD-16 by characteristics.
Characteristic UK men with prostate cancer
(N=2,766)
N % p
Age <60 years 325 15 <0.01
60-69 years 956 9.4
70-79 years 899 7.1
80+ years 586 13.5
Deprivation (Quintile of
socio-economic
deprivation)
Most affluent 1 480 6 0.07
2 608 7.8
3 584 9.7
4 529 12.6
Least affluent 5 498 18.3
Ethnicity White 2,101 8.9 < 0.01
Non-White 126 15.4
Long term conditions 0 403 4.7 < 0.01
1 660 6.4
2 668 11.5
3+ 1,035 22.4
Consulted for mental
health related
problem
No 1,795 7.6 < 0.01
Yes 883 17.9
Carer status No 1,855 8.6 < 0.01
Yes 766 11.2
Legal marital status Married/Civil
Partner
1,986 8.5 < 0.01
Separated/
Divorced
331 15.7
Widowed 229 10.8
Single 130 12.3
Other 55 14.4
Employment status Employed 376 6.3 < 0.01
Unemployed 343 58.9
Retired 1,928 8.8
Other 36 17.4
Body Mass Index (Kg/m2) <25 623 7.41 < 0.01
25-30 1,005 7.66
>30 824 14.41
Stage I/II 1,331 8.1 < 0.01
III 548 9.4
IV 489 15.5
Treatment Active surveillance 188 6.6 < 0.01
Surgery alone 503 7.3
EBRT alone 196 8
Brachytherapy
alone
50 4.2
ADT alone 469 15.7
Watchful waiting 181 8.2
EBRT & ADT 702 9.6
Surgery & EBRT/
ADT
274 12
ADT & systemic 105 17.2
EBRT & systemic 98 19.4
Key: SD-16: Social Distress scale. EBRT: External beam radiotherapy. ADT:
Androgen deprivation therapy. Systemic (chemotherapy/Abiraterone/
Enzalutamide). p values represent level of significance in a chi-squared test,
significance was indicated at the 0.05 level.
Table 3
Logistic regression analyses for Social Distress.
Odds
Ratio
95%
Confidence
interval
p
Age <60 years 1
60–69 years 0.55 0.45–0.67 < 0.01
70–79 years 0.41 0.33–0.51 < 0.01
80+ years 0.69 0.54–0.88 < 0.01
Deprivation (Quintile
of socio-economic
deprivation)
Most affluent 1 1
2 1.28 1.11–1.49 < 0.01
3 1.43 1.23–1.66 < 0.01
4 1.66 1.42–1.95 < 0.01
Least affluent 5 2.3 1.95–2.72 < 0.01
Ethnicity White 1
Non-White 1.29 0.99–1.67 0.06
Long term conditions 0 1
1 1.38 1.18–1.61 < 0.01
2 2.63 2.25–3.08 < 0.01
3+ 5.37 4.61–6.27 < 0.01
Consulted for mental
health related
problem
No 1
Yes 2.23 2.00–2.48 < 0.01
Carer status No 1
Yes 1.32 1.19–1.47 < 0.01
Legal marital status Married/Civil
Partner
1
Separated/
Divorced
1.48 1.26–1.74 < 0.01
Widowed 1.07 0.89–1.29 0.46
Single 0.89 0.70–1.15 0.37
Other 1.56 1.10–2.23 0.01
Employment status Employed 1
Unemployed 11.58 9.16–14.63 < 0.01
Retired 1.19 1.02–1.39 0.02
Other 2.39 1.55–3.7 < 0.01
Body Mass Index (Kg/
m2)
<25 1
25-30 1.01 0.89–1.15 0.87
>30 1.52 1.33–1.75 < 0.01
Stage I/II 1
III 1.09 0.96–1.23 0.18
IV 1.44 1.24–1.67 < 0.01
Treatment Active
surveillance
1
Surgery alone 1.1 0.89–1.36 0.36
EBRT alone 1.19 0.93–1.54 0.17
Brachytherapy
alone
0.54 0.36–0.81 < 0.01
ADT alone 2 1.58–2.53 < 0.01
Watchful waiting 1.2 0.92–1.56 0.17
EBRT & ADT 1.4 1.14–1.73 < 0.01
Surgery & EBRT/
ADT
1.83 1.44–2.33 < 0.01
ADT & systemic 2.79 2.01–3.87 < 0.01
EBRT & systemic 3.59 2.58–5 < 0.01
Key: EBRT: External beam radiotherapy. ADT: Androgen deprivation therapy.
Systemic (chemotherapy/Abiraterone/Enzalutamide). The odds ratios with
their 95% confidence intervals were estimated by multivariate logistic regres-
sion after controlling for the sociodemographic and clinical variables listed. An
odds ratio greater than 1 represents a greater odds than the first group listed
(reference category) of reporting social distress. To check for multi-collinearity
between stage and treatment, two models were run. The first, shown above,
included ‘stage at diagnosis’ in the model and the second excluded ‘stage at
diagnosis’ from the model. The Odds Ratios for both models changed very little.
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older men, their ‘life stage’ maybe reflects struggling with age-related
fatigue and general physical decline, impacting recovery from treat-
ment [24]. Multi-morbidity is strongly associated with older age, with
the proportion of people in England with one or more diagnosed disease
(s) increasing with age until plateauing at over 90% in the 85-plus age
groups [28]. Having ≥3 comorbid LTCs increased the odds of social
distress, almost five-fold. This echoes findings that multi-morbidity
tends to be negatively associated with health related quality of life in
men with PCa [29]. Similarly, a Danish study demonstrated the ex-
pressed need for rehabilitation was significantly increased in cancer
patients with multi-morbidity and this was particularly marked in men
with PCa [30].
There were a number of other health related factors independently
associated with social distress but to a lesser extent: Men who had
consulted a health/social care professional for mental health related
problems and those with a BMI > 30 had greater odds of being socially
distressed. PCa related clinical and treatment factors of most im-
portance concerning social distress were being diagnosed with Stage IV
disease and/or receiving systemic treatment or ADT. There may well be
a case for, in addition to PCa related factors, multi-morbidity and other
health related problems to be included in modelling for risk-stratified
care planning. Referral for specialist rehabilitation (e.g. occupational
therapy, physiotherapy, social work) may need to be a consideration for
those with complex health problems.
The odds of men who lived in the areas of greatest socio-economic
deprivation reporting significant social distress were almost twice
compared with their most affluent counterparts. The proportion of
distressed men increased across the socio-economic deprivation tra-
jectory. The link between deprivation and poorer QoL has been ob-
served elsewhere with role, social and emotional functioning, measured
using the EORTC-QLQ-C30 at 12 months post radical prostatectomy,
found to be influenced by income at the time of diagnosis [31]. Other
indicators of greater social distress included being separated or di-
vorced and having caring responsibilities. Having caring responsi-
bilities impacted all three Social Distress subscales. As the population
ages, ‘mutual caring’ is likely to become commonplace. Men with PCa
Table 4
Logistic regression analyses for three SD-16 subscales.
Subscale Everyday living Money Matters Self and others
Characteristics Odds
Ratio
95% Confidence
interval
p Odds
Ratio
95% Confidence
interval
p Odds
Ratio
95% Confidence
interval
p
Age < 60 years 1 1 1
60–69 years 0.87 0.70–1.08 0.2 0.61 0.53–0.71 < 0.01 0.49 0.42–0.57 < 0.01
70–79 years 1.04 0.82–1.31 0.75 0.44 0.37–0.51 < 0.01 0.34 0.29–0.4 < 0.01
80+ years 1.98 1.55–2.53 < 0.01 0.49 0.40–0.6 < 0.01 0.44 0.36–0.54 < 0.01
Deprivation (Quintile of socio-
economic deprivation)
Most affluent 1 1 1
2 1.27 1.12–1.43 < 0.01 1.31 1.15–1.48 < 0.01 1.14 1.01–1.28 0.03
3 1.36 1.20–1.55 < 0.01 1.36 1.20–1.55 < 0.01 1.08 0.95–1.23 0.23
4 1.56 1.36–1.79 < 0.01 1.69 1.48–1.94 < 0.01 1.36 1.19–1.56 < 0.01
Least affluent 5 2.26 1.96–2.61 < 0.01 2.19 1.89–2.53 < 0.01 1.6 1.38–1.85 < 0.01
Ethnicity White 1 1 1
Non-White 1.04 0.81–1.33 0.79 1.79 1.46–2.19 < 0.01 1.08 0.85–1.36 0.53
Long term conditions 0 1 1 1
1 1.55 1.35–1.77 < 0.01 1.2 1.07–1.34 < 0.01 1.14 1.01–1.27 0.03
2 2.77 2.42–3.18 < 0.01 1.7 1.50–1.92 < 0.01 1.78 1.57–2.01 < 0.01
3+ 6.29 5.50–7.2 < 0.01 2.34 2.06–2.67 < 0.01 2.44 2.15–2.78 < 0.01
Consulted for mental health
related problem
No 1 1 1
Yes 1.77 1.60–1.95 < 0.01 1.66 1.51–1.83 < 0.01 2.5 2.28–2.74 < 0.01
Carer status No 1 1 1
Yes 1.16 1.06–1.28 < 0.01 1.53 1.39–1.67 < 0.01 1.48 1.35–1.62 < 0.01
Legal marital status Married/Civil
Partner
1 1 1
Separated/Divorced 1.21 1.04–1.41 0.02 1.64 1.43–1.88 < 0.01 1.45 1.26–1.67 < 0.01
Widowed 1.12 0.97–1.29 0.14 1.24 1.05–1.47 0.01 1.38 1.18–1.62 < 0.01
Single 1.05 0.85–1.3 0.64 0.99 0.81–1.22 0.94 1.15 0.94–1.4 0.18
Other 1.34 0.96–1.88 0.09 1.42 1.04–1.94 0.03 1.44 1.05–1.96 0.02
Employment status Employed 1 1 1
Unemployed 13.18 10.36–16.75 < 0.01 5.81 4.69–7.19 < 0.01 4.55 3.68–5.63 < 0.01
Retired 2.12 1.81–2.49 < 0.01 0.57 0.51–0.63 < 0.01 1.02 0.90–1.15 0.77
Other 3.1 1.99–4.83 < 0.01 1.98 1.40–2.8 < 0.01 1.79 1.22–2.62 < 0.01
Body Mass Index < 25 1 1
25-30 0.98 0.88–1.09 0.67 1.01 0.91–1.12 0.86 1.01 0.91–1.12 0.82
> 30 1.65 1.47–1.85 < 0.01 1.29 1.15–1.46 < 0.01 1.4 1.24–1.58 < 0.01
Stage I/II 1 1 1
III 1.13 1.02–1.25 0.02 1.08 0.97–1.2 0.14 1.12 1.01–1.25 0.03
IV 1.44 1.27–1.63 < 0.01 1.47 1.28–1.68 < 0.01 1.26 1.10–1.45 < 0.01
Treatment Active surveillance 1 1 1
Surgery alone 1.24 1.02–1.5 0.03 1.21 1.02–1.43 0.03 1.36 1.14–1.62 < 0.01
EBRT alone 1.29 1.04–1.61 0.02 1.41 1.14–1.73 < 0.01 1.33 1.07–1.65 0.01
Brachytherapy
alone
0.8 0.57–1.12 0.19 0.85 0.64–1.13 0.27 0.9 0.67–1.21 0.48
ADT alone 2.15 1.75–2.63 < 0.01 1.55 1.25–1.91 < 0.01 1.74 1.41–2.15 < 0.01
Watchful waiting 1.34 1.07–1.67 0.01 1.17 0.93–1.47 0.17 1.32 1.05–1.66 0.02
EBRT & ADT 1.53 1.27–1.84 < 0.01 1.37 1.15–1.63 < 0.01 1.65 1.38–1.97 < 0.01
Surgery & EBRT/
ADT
1.58 1.27–1.98 < 0.01 1.8 1.47–2.21 < 0.01 1.96 1.59–2.41 < 0.01
ADT & systemic 3.31 2.49–4.4 < 0.01 1.8 1.33–2.45 < 0.01 2.71 2.01–3.64 < 0.01
EBRT & systemic 4.63 3.46–6.19 < 0.01 2.07 1.51–2.83 < 0.01 2.65 1.95–3.6 < 0.01
Key: SD-16: Social Distress scale. EBRT: External beam radiotherapy. ADT: Androgen deprivation therapy. Systemic (chemotherapy/Abiraterone/Enzalutamide).
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caring for someone else may have to make difficult choices regarding
treatment, based in part on their caring responsibilities. Checking ‘carer
status’ across the patient pathway may help ensure discussion and
support are provided in a timely manner. Being of non-white ethnicity
was not associated with overall social distress, with Everyday Living or
Self and Others subscales, but was of significance in the Money Matters
subscale. In the UK, medical costs are paid for by the NHS. Where
health costs are not part of a national health system the disparity be-
tween white and non-white ethnic groups may be wider. A qualitative
metasynthesis of ethnicity and the experience of PCa highlighted the
marked financial burden arising from the cost of treatment and services
experienced by minority ethnic groups in the USA [32].
Although this survey included a very large sample, there are a
number of limitations. The data reported are cross-sectional and
therefore, although associations between variables may be strong,
causation cannot be inferred. The data provide a ‘snap-shot’ of the ex-
perience of men between 18–42 months post PCa diagnosis. Stage of
disease at the time of the survey was not known, therefore no measure
of disease progression was available. The ProtecT study demonstrated
that by 12 months, men with clinically localised disease at diagnosis
had relatively stable physical and mental health scores which remained
steady over the following five years [2]. In the LAPCD study almost two
thirds of men were diagnosed with stage I or II disease, and therefore it
seems possible that, as with physical and mental health, social distress
may be relatively stable over this time period. Men with advancing
disease may experience greater levels of social distress but this cannot
be ascertained from the available data. Likewise, ongoing treatments
may influence social distress but data were unavailable to test this. Self-
report was the only way to collect all treatment information. Although
less reliable than medical record review, agreement between self-report
and record review has been found to be excellent for surgery and
radiotherapy, with decreasing agreement for hormone therapies [33].
Many different treatment combinations were reported; some combina-
tions too small to report separately. Based on clinical feedback, ten
single and combination treatment groups with the largest numbers of
men and highest clinical relevance were included in analyses. As data
were missing both from cancer registration systems (e.g. stage at di-
agnosis) and from participant self-report (e.g. height and weight for
BMI calculation), generalisation of the results should be undertaken
with some caution. However, as the overall response rate was reason-
ably high (> 60%) and the sample size large, these findings remain the
most comprehensive and highest quality available to date. As the re-
sponse rates of non-white men and of men living in areas of greater
socio-economic deprivation were lower than that of white men and of
men living in less deprived areas, respectively, the level of social dis-
tress reported may be an underestimate. Co-morbidities were self-re-
ported, which may be thought unreliable. However, a recent study
demonstrated comorbidities reported by men with PCa were similar to
those extracted from medical records [34]. Lastly, men who did not
self-report or were unsure about their treatment were not included in
the analyses; however, the pattern in the results was similar when all
respondents were included in the analyses (results not shown). Ideally,
we would have liked to obtain general population data from across the
UK but this was beyond the scope of this research.
5. Conclusions
This study has highlighted that the majority of men living 18–42
months following a diagnosis of PCa report little social distress. We
have been able to identify common factors associated with social dis-
tress which mirror closely our earlier findings from a PROMs survey of
people following a diagnosis of colorectal cancer in England [10]. The
identification of these factors has direct and valuable clinical applica-
tion. Awareness of the most vulnerable groups of men is essential to
ensure appropriate provision of support. The social distress risk factors
identified in this study can easily be ‘flagged’ in the clinical setting
without any major resource expenditure. Reference to a simple check-
list (Box 1) to remind clinicians of men at greatest risk of social distress
may inform judicious and risk-stratified utilisation of frequently stret-
ched psychosocial support and rehabilitation resources. For policy-
makers, commissioners and providers of health and social care, an
understanding of these risk factors will support delivery of appropriate
targeted interventions to maximise quality of survival.
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